Wellysis Secures FDA 510(k) Clearance for AI-Powered ECG Analysis Software, S-Patch CardioAI

The FDA clearance for S-Patch CardioAI allows Wellysis to offer an integrated solution for both ECG data acquisition and AI-powered analysis in the U.S. market. This expansion enables healthcare solution providers to incorporate CardioAI into web and mobile applications, potentially broadening its use among remote patient monitoring providers, Independent Diagnostic Testing Facilities, and Clinical Research Organizations.

The software's design aims to streamline ECG review workflows by automating analysis and supporting healthcare professionals in interpreting data. This capability addresses the challenge of managing increasing ECG monitoring volumes, which often require more efficient review processes across various remote cardiac monitoring settings.

Wellysis plans to introduce CardioAI to its existing U.S. S-Patch customers and expand its offerings through subscription and per-test commercial models. The company's U.S. subsidiary, established in 2023, has shown growth, with revenue quadrupling from 2024 to 2025, suggesting a developing market presence that could support the adoption of this new AI-powered software.

As a company spun off from Samsung SDS, Wellysis has established a foundation in wearable ECG monitoring, with its S-Patch series holding regulatory clearances in the U.S., Korea, and Europe. The FDA clearance for CardioAI builds upon this existing regulatory track record, indicating a focused effort to integrate AI capabilities into its validated medical device portfolio.